key: cord-0987860-l5fckypj
authors: Castaldelli-Maia, J. M.; Marziali, M. E.; Lu, Z.; Martins, S. S.
title: Investigating the effect of national government physical distancing measures on depression and anxiety during the COVID-19 pandemic through meta-analysis and meta-regression
date: 2020-09-02
journal: nan
DOI: 10.1101/2020.08.28.20184119
sha: 0e00d02853f01856e52602afee8e66467be8f421
doc_id: 987860
cord_uid: l5fckypj

Background: COVID-19 physical distancing measures can potentially increase the likelihood of mental disorders. It is unknown whether these measures are associated with depression and anxiety. Objectives: To investigate meta-analytic global levels of depression and anxiety during the COVID-19 pandemic and how implementation of mitigation strategies (i.e. public transportation closures, stay-at-home orders, etc.) impacted such disorders. Data sources: Pubmed, MEDLINE, Web of Science, BIOSIS Citation Index, Current Content Connect, PsycINFO, CINAHL, medRxiv, and PsyArXiv databases for depression and anxiety prevalences; Oxford Covid-19 Government Response Tracker for the containment and closure policies indexes; Global Burden of Disease Study for previous levels of depression and anxiety. Study eligibility criteria: Original studies conducted during COVID-19 pandemic, which assessed categorical depression and anxiety, using PHQ-9 and GAD-7 scales (cutoff [≥] 10). Participants and interventions: General population, healthcare providers, students, and patients. National physical distancing measures. Study appraisal and synthesis methods: Meta-analysis and meta-regresssion. Results: In total, 226,638 individuals were assessed within the 60 included studies. Global prevalence of both depression and anxiety during COVID-19 pandemic were 24.0% and 21.3%, respectively. There was a wide variance in the prevalence of both anxiety and depression reported in different regions of the world and countries. Asia, and China particularly, had the lowest prevalence of both disorders. Regarding the impact of mitigation strategies on mental health, only public transportation closures increased anxiety prevalence. Limitations: Country-level data on physical distancing measures and previous anxiety/depression may not necessarily reflect local (i.e., city-specific) contexts. Conclusions and implications of key findings: Mental health concerns should not be viewed only as a delayed consequence of the COVID-19 pandemic, but also as a concurrent epidemic. Our data provides support for policy-makers to consider real-time enhanced mental health services, and increase initiatives to foster positive mental health outcomes.

COVID-19 is an unprecedented health emergency, affecting millions of individuals across the globe. 1 SARS-Coronavirus-2, the virus which causes COVID-19, is transmitted personto-person via respiratory droplets. 2 In order to prevent and lessen spread, countries began implementing mitigation strategies, such as: stay-at-home or shelter-in-place orders, international travel constraints, closure of schools and workplaces, and movement limitations 3 . Despite being necessary public health measures, researchers have speculated that these measures could increase feelings of social isolation and loneliness 4 ; this is of importance, as previous studies have demonstrated that social isolation could impact the likelihood of mental disorders 5 and physical health outcomes 6 . As of yet, it still remains unclear to what extent the COVID-19 mitigation strategies could impact mental health. Thus, it is imperative to investigate the levels of mental health disorders and the possible impacts of social distancing measures on mental health outcomes 7 .

Prior to the pandemic, depression and anxiety were the most prevalent mental health disorders in the world 8 . These mental health disorders have also been connected to social isolation during COVID-19 in local studies 9 . During the COVID-19 pandemic, the levels of such disorders have increased. Pappa et al. 10 conducted a meta-analysis with thirteen studies that included 33,062 healthcare workers during COVID-19, and reported a prevalence of 23.2% and 22.8% of anxiety and depression, respectively. These prevalences are greater than those found in the pre-COVID-19 era. 8 Several studies have assessed depression and anxiety using scales involving self-reporting during the pandemic. 11-70 These studies report a wide range of prevalence estimates, which appear to be dependent on the sub-population of interest (i.e., general population, healthcare providers, students, patients), and the geographic location within which the study is focused. There is a need for meta-analytic investigations generating global prevalence measures for both depression and anxiety during the pandemic, with additional exploration via subgroup analysis.

Further, there are mixed findings regarding the effect of mitigation strategies on depression and anxiety during this pandemic. Previous research has demonstrated marked increases in online search trends for mental health topics (i.e., sleep disturbances, negative thoughts, anxiety, suicidal ideation) prior to the implementation of stay-at-home orders in the U.S.. 71 4 Further, an online qualitative study evaluated focus groups during the beginning of the social distancing measures in the U.K., where they found negative impacts on well-being and mental health after implementation of mitigation strategies. 72 Individuals who had lower pay, or vulnerable employment, were the most affected. 72 Thus, the effects of these physical distancing strategies may be time-sensitive. Moreover, there are varying ongoing physical distancing measures (i.e., school closures, workplace closures, public events cancellations, restrictions on the size of gatherings, public transport closures, stay-at-home orders, restrictions on internal movement between cities and regions within a country, and international travel controls) during different periods, depending on the location. 3 There is a need to explore whether these strategies have lasting impacts on depression and anxiety, taking different time of exposure thresholds to such physical distancing measures into account.

The present study aims to (1) investigate meta-analytic global levels of depression and anxiety during the COVID-19 pandemic, and (2) explore the effects of these mitigation strategies on depression and anxiety.

• Workplace closures (0 -no measures; 1 -recommend closing or recommend work from home; 2 -require closing or work from home for some sectors or categories of workers; 3 -require closing or work from home for all-but essential workplaces);

• Cancellation of public events (0 -no measures; 1 -recommend cancelling; 2 -require cancelling);

• Restrictions on gatherings (0 -no restrictions; 1 -restrictions on very large gatherings above 1000 people; 2 -restrictions on gatherings between 101-1000 people; 3restrictions on gatherings between 11-100 people; 4 -restrictions on gatherings of 10 people or less);

• Public transportation closures (0 -no measures; 1 -recommend closing or significantly reduce volume/route/means of transport available; 2 -require closing or prohibit most citizens from using it);

• Stay at home requirements (0 -no measures; 1 -recommend not leaving house; 2require not leaving house with exceptions for daily exercise, grocery shopping, and 'essential' trips; 3 -require not leaving house with minimal exceptions);

• Restrictions on internal movement: record restrictions on internal movement between cities/regions (0 -no measures; 1 -recommend not to travel between regions/cities; 2 -internal movement restrictions in place); and,

• International travel controls: record restrictions on international travel for foreign travelers (0 -no restrictions; 1 -screening arrivals; 2 -quarantine arrivals from some or all regions; 3 -ban arrivals from some regions; 4 -ban on all regions or total border closure).

For each study included in the meta-analysis, we calculated the mean of the daily ordinal score of each of the above indexes, during two timeframes:

• 2-week: weeks before the start date of the study until the end date of the study; and, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 9 • 4-week: weeks before the start date of the study until the end date of the study.

We included all the rates (crude number cases/total number of individuals) in separate metaanalysis models for depression (PHQ-9 >= 10) and anxiety (GAD-7 >= 10). One study provided weighted rates for the outcomes only. 24 We used a random-effects model because high heterogeneity was expected. We calculated I 2 as a measure of between-study heterogeneity. Data were analyzed using OpenMetanalyst, 79 which makes use of R metafor package. 80 The threshold for significance was set to p-values of less than 0.05. In addition, we carried out further subgroup analysis models by population type (general, healthcare providers, students, patients, and mixed), region of the world (Asia, Europe, and Other), country (China and other), income level (high-income, and low-and middle-income), and non-national status (local studies were defined as those restricted to either a city or a state/province/region within a country, versus national studies).

Finally, we investigated the impact of physical distancing measures on depression and anxiety through meta-regression models. 81 Separate models were carried out for different timeframes of physical distancing measures (2 and 4 weeks). Models adjusted for gender, sub-populations, timepoint when study began, region of the world, local status and previous levels of either depression or anxiety, depending on the outcome. Country indicators were not included in these models because of the strong correlation with earlier levels of depression and anxiety variables, which were collected based on previous data by each country. Metaregression was used instead of subgroup analyses (i.e., different levels of social measures implementation) to allow for the use of continuous and multiple covariates. The randomeffects meta-regression used residual restricted maximum likelihood to measure betweenstudy variance (τ2) with a Knapp-Hartung modification as recommended models. 81 10

Table S1 presents the key-information of the 60 studies included. Eight studies were split into subsamples, and two studies reported the same sample. We included 67 samples in the metaanalysis models. All studies were conducted in 2020 (compiled date range of study initiation to closure: January 24 th -May 31 st ), with a mean length of 15.4 days. In total, 226,638 individuals were included, with an average of 3,382 individuals per study. The mean age was 33.8 (range: 13-89) among samples that provided data on mean age and range, and the proportion of females included was 61.9% (range: 0-100). Few samples were representative (5.9%, N=4), and local (32.8%, N=22). Most samples were based in China (38.8%, N=26), and Asia in general (52.2%, N=35). General population samples were the most common (40.2%, N=27), followed by healthcare providers (23.8%, N=16), students (16.4%, N=11), and patients (8.9%, N=6). The vast majority of the samples used online methods (91.0%, N=61) and were peer-reviewed (64.1%, N=43). Table S2 presents the results of the quality assessment. All the included studies scored five or higher in such an assessment. Tables S3 and S4 present implementation of physical distancing measures and previous prevalence of depression and anxiety, respectively. S9 , and S10) found no significant differences by population type, country income level, or being a local study. Table 1 shows the results of the meta-regression models for depression. Both in the 2-and 4week physical distancing models, previous depression, older studies, and other region of the world than Asia/Europe were associated with depression. In addition, patient studies had a higher prevalence of depression in the 2-week physical distancing model. No significant association with physical distancing implementation measures was found in both models. Table 2 presents the results of the meta-regression models for anxiety. Both in the 2-and 4week physical distancing models, the closure of public transportation was associated with anxiety. Student studies had lower levels of anxiety in both models. No other significant association between physical distancing measures and depression or anxiety were found.

This study aimed to investigate levels of depression and anxiety during the COVID-19 pandemic and the effect of physical distancing measures on depression and anxiety. We found high global prevalences of both depression and anxiety during the COVID-19 pandemic (24.0% and 21.3%, respectively); however, there was a wide variance in the prevalence of both anxiety and depression reported at the region-and country-level. Asia, and China especially, presented lower levels of both anxiety and depression, compared to the other r and countries. Closure of public transportation increased levels of anxiety, independently of the timeframe (2 or 4 weeks post-transportation closure enactment). in Norway; 91 and 6.1-10.2% in Germany. 92 The only country to report potentially lower depression rates post-COVID-19 is Russia; however, pre-COVID-19 estimates range from 5.5% 83 to 31.2-37.8%, 93 a variation which may be the result of differing scales or methods for assessing depression. Overall, we observe a marked increase in depression prevalence in the post-COVID-19 era.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted September 2, 2020. .

Similarly, the prevalence of anxiety, as reported in the subgroup of Asian countries is largely greater subsequent to the onset of COVID-19. Rates of anxiety prior to COVID-19 ranged from: 3.0-5.8% in India; 83,94 3.1% in China; 83 3.2% in Nepal; 83 Our finding regarding the effect of public transportation closures on anxiety levels points to the importance of these systems to global populations. We understand that anxiety could emerge as a result of two fear/worry dimensions: not being able to achieve the basic needs and/or insecurity. Depending on the setting (i.e., rural, small to large metropolitan areas), there is a significant number of individuals who do not have an alternative way of transport (i.e., car, motorcycle) and are dependent on public transportation. 102 People in many different countries and cultural contexts rely on some method of public transport for getting food, clothing, education, shelter, healthcare, sanitation, 103 such as transport within metropolitan areas to places of employment. 104 It is thus reasonable to theorize that anxious anticipatory thinking could emerge in people dependent on public transport. These are core symptoms of many anxiety disorders, 105 which are captured by our anxiety outcome measure (GAD-7). In addition to worry regarding reliability of public transport, anxiety could grow from increased risk of assault and harassment resultant from fewer bystanders accessing this method of transportation. 106 Considering that mitigation strategies in the COVID era have involved significantly reducing the volume of passengers, the number of routes, and the means of transport available, 107 closures of these systems can work to generate excessive anxiety and worry. 108 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted September 2, 2020. .

Country-level data of physical distancing measures and previous anxiety or depression is an important limitation of the present study. However, we included data from 67 different samples from 26 countries, within five global regions (Asia, Africa, America, Europe, and Middle-East), totaling almost 200,000 individuals in each meta-analysis. In addition, we used just one outcome measure per disorder (PHQ-9 and GAD-7), to avoid outcome measure bias, common in meta-analysis studies. Unfortunately, we were not able to include age as a covariate in the meta-regression models due to lack of descriptive data. A portion of the included samples (35.9%, N=24) were not peer-reviewed. Notably, inclusion of data from pre-print repositories could be seen as both a strength and limitation, in that the inclusion of the most recent data is of utmost importance. Results should be interpreted with caution.

The COVID-19 pandemic, and the resulting physical distancing measures to mitigate viral spread, has impacted population mental health worldwide. Despite finding a wide variation in anxiety and depression levels across countries and regions of the world, high prevalence of mental health disorders is a considerable concern during the COVID era. Thus, mental health outcomes should not be addressed as a delayed consequence of the COVID-19 pandemic, but rather as an ongoing and concurrent epidemic (i.e., a syndemic). We also observed an association between restrictions and closures of public transportation systems and an increase in anxiety levels. These results have important implications for policymakers. There is an urgent need for the healthcare sector to increase now support for prevention and early intervention of depression and anxiety.

None . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted September 2, 2020. . Pappa S, Ntella V, Giannakas T, Giannakoulis VG, Papoutsi E, Katsaounou P.

Prevalence of depression, anxiety, and insomnia among healthcare workers during the COVID-19 pandemic: A systematic review and meta-analysis. Brain Behav Immun. 2020;88:901-907.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted September 2, 2020. .

Ahmad . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 2, 2020. . Consolo U, Bellini P, Bencivenni D, Iani C, Checchi V. Epidemiological Aspects and health concern in the era of COVID-19. Psychiatry Res. 2020;290:113117.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 2, 2020. .

Lai . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 2, 2020. .

Qian . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 2, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 2, 2020. .

Zhao . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 2, 2020. Records excluded (n = 298), by the following reasons:

Full-text articles assessed for eligibility (n = 95)

Full-text articles excluded (n = 37), by the following reasons:

Only PHQ-2 and/or GAD-2 (n=5) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 2, 2020. . Proportion . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 2, 2020. Proportion . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 2, 2020. . https://doi.org/10.1101/2020.08.28.20184119 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 2, 2020. . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 2, 2020. 

Protocol and registration 5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.

Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.

Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.

Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.

Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).

Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.

Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.

12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.

Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means). 

Risk of bias across studies 15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).

Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.

Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.

Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.

Risk of bias within studies 19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).

Results of individual studies 20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. 

Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).

Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).

Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.

Funding 27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. 

A reporting checklist for Authors, Editors, and Reviewers of Meta-analyses of Observational Studies. You must report the page number in your manuscript where you consider each of the items listed in this checklist. If you have not included this information, either revise your manuscript accordingly before submitting or note N/A. 

Description of relevance or appropriateness of studies assembled for assessing the hypothesis to be tested Rationale for the selection and coding of data (eg, sound clinical principles or convenience) Documentation of how data were classified and coded (eg, multiple raters, blinding, and interrater reliability) Assessment of confounding (eg, comparability of cases and controls in studies where appropriate . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 2, 2020. 

Reported on Page No. Assessment of study quality, including blinding of quality assessors; stratification or regression on possible predictors of study results Assessment of heterogeneity Description of statistical methods (eg, complete description of fixed or random effects models, justification of whether the chosen models account for predictors of study results, dose-response models, or cumulative meta-analysis) in sufficient detail to be replicated Provision of appropriate tables and graphics

Table giving descriptive information for each study included Results of sensitivity testing (eg, subgroup analysis) Indication of statistical uncertainty of findings

Quantitative assessment of bias (eg, publication bias) Justification for exclusion (eg, exclusion of non-English-language citations) Assessment of quality of included studies

Consideration of alternative explanations for observed results Generalization of the conclusions (ie, appropriate for the data presented and within the domain of the literature review) Guidelines for future research Disclosure of funding source

Once you have completed this checklist, please save a copy and upload it as part of your submission. DO NOT include this checklist as part of the main manuscript document. It must be uploaded as a separate file.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 2, 2020. Proportion . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 2, 2020. 

The COVID-19 epidemic

Transmission, Diagnosis, and Treatment of Coronavirus Disease

Oxford COVID-19 Government Response Tracker. Blavatnik School of Government

Physical Distancing in COVID-19 May Exacerbate Experiences of Social Isolation among People Living with HIV

The outbreak of COVID-19 coronavirus and its impact on global mental health

Social relationships and health

8 GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories

COVID-19 Pandemic: Psycho-social

Consequences During the Social Distancing Period Among Najran City Population

Proportion . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 2, 2020. Proportion . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 2, 2020. . https://doi.org/10.1101/2020.08.28.20184119 doi: medRxiv preprint